Article info

other Versions

PDF

Extended report
Patient-reported outcomes from a phase 3 study of baricitinib versus placebo or adalimumab in rheumatoid arthritis: secondary analyses from the RA-BEAM study

Authors

  1. Correspondence to Professor Edward C Keystone, The Rebecca MacDonald Centre for Arthritis and Autoimmunity, Mt Sinai Hospital, University of Toronto, Toronto, Canada; ed.keystone{at}sinaihealthsystem.ca
View Full Text

Citation

Keystone EC, Taylor PC, Tanaka Y, et al
Patient-reported outcomes from a phase 3 study of baricitinib versus placebo or adalimumab in rheumatoid arthritis: secondary analyses from the RA-BEAM study

Publication history

  • Received February 3, 2017
  • Revised June 22, 2017
  • Accepted June 24, 2017
  • First published August 10, 2017.

Article Versions

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.